Miruvor
Sign up
The short answer

What studies of Ursodiol / UDCA (ursodeoxycholic acid) found

2papers on Ursodiol / UDCA (ursodeoxycholic acid)
132people in 1 study testing Ursodiol / UDCA (ursodeoxycholic acid) alone, and 23,560 patients in 1 health-record study, counted apart
1randomised trial, the strongest kind of study

At a glance, by condition

Long COVID: D Little or no difference

Based on the strongest evidence, the placebo trial (very low certainty), for overall symptoms.

1 outcome rated · see each below

Preventing long COVID: D Little or no difference

Based on the strongest evidence, compared with another group, not randomised (very low certainty): 3 findings, all D.

3 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: For long COVID, studies found little or no difference with Ursodiol / UDCA (ursodeoxycholic acid). For preventing long COVID, studies found little or no difference with Ursodiol / UDCA (ursodeoxycholic acid). If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 2 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. C
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. Ursodiol / UDCA (ursodeoxycholic acid) · Long COVID is hereUrsodiol / UDCA (ursodeoxycholic acid) · Preventing long COVID is hereD
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Daily life and health overall

Overall symptoms1 study · 132 people took Ursodiol / UDCA (ursodeoxycholic acid) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 396 people found no clear difference; a small benefit can't be ruled out.

The placebo trial396 randomised · 14 days · 900 mg once daily, 14 days

No clear difference in overall symptoms.

The evidence is very uncertain about the effect of Ursodiol / UDCA (ursodeoxycholic acid) on overall symptoms in long COVID. Little or no difference · very low certainty D

  • Some concerns about bias (RoB 2)
  • One trial of 396 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Neither Metformin nor Ursodeoxycholic Acid Effectively Treats Postacute Sequelae of COVID-19 : A Randomized Clinical Trial. (2026)

    People in the study
    396 randomised
    Dose
    900 mg once daily, 14 days
    Outcome
    Difference in probability of recovery postacute sequelae of SARS-CoV-2 infection (PASC) index
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns

Preventing long COVID

Breathlessness1 study · 23,560 people took Ursodiol / UDCA (ursodeoxycholic acid) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.

Compared with another group, not randomised469,108 in the study · 90-day period preceding cohort entry · at least one UDCA prescription within the 90-day period preceding cohort entry

No clear difference in breathlessness.

The evidence is very uncertain about the effect of Ursodiol / UDCA (ursodeoxycholic acid) on breathlessness later, when given during acute COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
See the 1 study
  1. Ursodeoxycholic acid and long COVID in steatotic liver disease: a nationwide cohort study. (2026)

    People in the study
    469,108 in the study
    Dose
    at least one UDCA prescription within the 90-day period preceding cohort entry
    Outcome
    interstitial lung disease
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: Age, sex, insurance type, dominant COVID-19 variant, comorbidities, concomitant medications, Charlson Comorbidity Index, COVID-19 vaccination history, lifestyle factors, SLD subtype Age, sex, insurance type, and dominant COVID-19 variant were assessed at cohort entry.
    Selection of participants
    Moderate. comparison group: Patients without a documented UDCA prescription during the 90-day window were classified as non-users and served as the reference group. Patients without a documented UDCA prescription during this 90-day window were classified as non-users and served as the reference group.
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: extent of missing data was minimal Given the use of NHIS- and registry-based administrative data, the extent of missing data was minimal.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified secondary outcome
Depression1 study · 23,560 people took Ursodiol / UDCA (ursodeoxycholic acid) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.

Compared with another group, not randomised469,108 in the study · 90-day period preceding cohort entry · at least one UDCA prescription within the 90-day period preceding cohort entry

No clear difference in depression.

The evidence is very uncertain about the effect of Ursodiol / UDCA (ursodeoxycholic acid) on depression later, when given during acute COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
See the 1 study
  1. Ursodeoxycholic acid and long COVID in steatotic liver disease: a nationwide cohort study. (2026)

    People in the study
    469,108 in the study
    Dose
    at least one UDCA prescription within the 90-day period preceding cohort entry
    Outcome
    depression
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: Age, sex, insurance type, dominant COVID-19 variant, comorbidities, concomitant medications, Charlson Comorbidity Index, COVID-19 vaccination history, lifestyle factors, SLD subtype Age, sex, insurance type, and dominant COVID-19 variant were assessed at cohort entry.
    Selection of participants
    Moderate. comparison group: Patients without a documented UDCA prescription during the 90-day window were classified as non-users and served as the reference group. Patients without a documented UDCA prescription during this 90-day window were classified as non-users and served as the reference group.
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: extent of missing data was minimal Given the use of NHIS- and registry-based administrative data, the extent of missing data was minimal.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified secondary outcome
Sleep1 study · 23,560 people took Ursodiol / UDCA (ursodeoxycholic acid) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.

Compared with another group, not randomised469,108 in the study · 90-day period preceding cohort entry · at least one UDCA prescription within the 90-day period preceding cohort entry

No clear difference in sleep.

The evidence is very uncertain about the effect of Ursodiol / UDCA (ursodeoxycholic acid) on sleep later, when given during acute COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
See the 1 study
  1. Ursodeoxycholic acid and long COVID in steatotic liver disease: a nationwide cohort study. (2026)

    People in the study
    469,108 in the study
    Dose
    at least one UDCA prescription within the 90-day period preceding cohort entry
    Outcome
    insomnia
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: Age, sex, insurance type, dominant COVID-19 variant, comorbidities, concomitant medications, Charlson Comorbidity Index, COVID-19 vaccination history, lifestyle factors, SLD subtype Age, sex, insurance type, and dominant COVID-19 variant were assessed at cohort entry.
    Selection of participants
    Moderate. comparison group: Patients without a documented UDCA prescription during the 90-day window were classified as non-users and served as the reference group. Patients without a documented UDCA prescription during this 90-day window were classified as non-users and served as the reference group.
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: extent of missing data was minimal Given the use of NHIS- and registry-based administrative data, the extent of missing data was minimal.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified secondary outcome

Side effects

No study of this treatment alone reported side effects we could read.

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    900 mg at the start

  2. 2Top dose

    Most often 900 mg (1 of 1 studies)

Doses across 1 study

900 to 900 mg.

Each study’s dose, as printed

All papers

  1. Ursodeoxycholic acid and long COVID in steatotic liver disease: a nationwide cohort study.2026 · compared with another group · 469,108 in the study
    Summary

    This nationwide retrospective cohort study used the Korean COVID-19 registry linked to National Health Insurance Service claims data (2019–2022) to examine whether pre-infection ursodeoxycholic acid (UDCA) use was associated with long COVID outcomes in patients with steatotic liver disease (SLD) and COVID-19. The base cohort included 469,108 patients with SLD infected with COVID-19; 23,560 (5.0%) were UDCA users and 445,548 (95.0%) were non-users. UDCA exposure was defined as at least one prescription within the 90-day period preceding cohort entry. The study assessed 20 incident long COVID conditions across eight organ systems from 84 days after infection, with median follow-up ranging from 134.3 to 141.6 days. After propensity score fine stratification, UDCA use was not associated with reduced risk for most long COVID outcomes. A protective association was observed for atrial fibrillation (HR 0.51, 95% CI 0.30–0.88), whereas increased risks were found for type 2 diabetes mellitus (HR 1.24, 95% CI 1.09–1.42) and epilepsy (HR 1.69, 95% CI 1.09–2.61). No harms of UDCA were reported for this study. The authors state that the observational design precludes causal inference and residual confounding cannot be completely excluded.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime